RxAdvocate March, 2025 — Newsletter

March 3 RxAdvocate March, 2025 — Newsletter

Alyftrek Approved for Cystic Fibrosis Treatment

On December 20, 2024, the FDA approved Vertex Pharmaceuticals’ Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor), a drug used to treat cystic fibrosis in patients 6 years of age and older. Cystic Fibrosis affects approximately 40,000 people in the United States and is a genetic disorder that affects the lungs, pancreas, and other organs.

During clinical trials, once-daily Alyftrek was found to be as good as Vertex’s twice-daily Trikafta in improving lung function and showed greater reduction in sweat chloride levels, a sign of improved clinical outcomes for cystic fibrosis patients. Clinical trials also showed a safety profile similar to that of Trikafta.

Alyftrek was launched in January 2025 with an annual wholesale acquisition cost (WAC) of $370,269, 7% higher than Trikafta. Given Alyftrek’s enhanced efficacy in reducing sweat chloride levels and more patient friendly once-daily dosing, it is expected that Vertex will successfully transition most eligible patients from Trikafta to Alyftrek within a year or two after approval. Alyftrek’s approval further solidifies Vertex Pharmaceuticals’ hold on a significant share of the cystic fibrosis market, treating more than half of patients worldwide.

National GLP-1 Supply Update

Recently, the FDA has announced the status change of several glucagon-like peptide 1 (GLP-1) medications that have been on their drug shortage list. Tirzepatide (Mounjaro, Zepbound) was lifted from the drug shortage list on 10/2/24, however after litigation requesting reevaluation of availability, the removal from the drug shortage list was paused.

On 12/19/24 the FDA confirmed that the drug shortage of Tirzepatide, that started in 2022 was resolved, and it would be removed from the drug shortage list. On 2/21/25 the FDA announced that the shortage of semaglutide (Ozempic, Wegovy) is resolved. Due to increased demand, this medication has been in shortage since 2022. Dulaglutide (Trulicity) and liraglutide (Victoza) are currently still on the drug shortage list.

Resource

Kidney Awareness Month

March is Kidney Awareness Month, a time to highlight the vital role our kidneys play in maintaining overall health. The kidneys are responsible for filtering waste from the blood, regulating blood pressure, and balancing electrolytes, among other essential functions. However, kidney disease can often go unnoticed until it becomes severe, making early detection crucial.

The National Kidney Foundation provides valuable resources to educate the public about kidney function and the importance of kidney health. The National Kidney Foundation website outlines the ways kidneys work and the steps individuals can take to protect them, such as monitoring blood pressure and staying hydrated. During Kidney Awareness Month, it’s important to raise awareness about kidney disease and encourage regular screenings for those at risk.

Welcome to Spring!

Spring has finally arrived, bringing with it a sense of renewal and endless possibilities. As flowers begins to bloom and the days get longer, we’re reminded of the potential for new beginnings. It’s the perfect time to shake off the winter blues and embrace fresh starts in all areas of life.

One of the best ways to make the most of this vibrant season is by focusing on personal growth and well-being. Spring offers an excellent opportunity to declutter both your space and your mind, helping you feel lighter and more focused. It’s also a great time to set new goals and reconnect with your passions, whether it’s through outdoor activities, creative pursuits, or simply taking time to appreciate the beauty around you.

Contact us